Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Decrease in Short Interest

Apollomics, Inc. (NASDAQ:APLMW) was the target of a significant drop in short interest in December. As of December 15th, there was short interest totalling 68,200 shares, a drop of 55.0% from the November 30th total of 151,500 shares. Based on an average daily trading volume, of 79,400 shares, the days-to-cover ratio is currently 0.9 days.

Apollomics Price Performance

Shares of NASDAQ:APLMW traded up $0.00 on Friday, reaching $0.01. 6,898 shares of the company traded hands, compared to its average volume of 52,916. The company’s 50 day moving average is $0.01 and its 200-day moving average is $0.01. Apollomics has a fifty-two week low of $0.01 and a fifty-two week high of $0.04.

Apollomics Company Profile

Apollomics, Inc, a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.